In an effort to smooth approval for its $106 billion merger, Pfizer and AstraZeneca are set to meet UK regulators on Tuesday who are wary a deal will lead to British job cuts. For its part, Pfizer says it has already made legally binding commitments with the UK government which include maintaining 20% of the company's R&D facilities in the U.K. and pledging to establish the combined company's corporate and tax residence in the UK. Warwick Business School's Hossam Zeitoun says that any promises Pfizer makes to the UK can easily be reversed if conditions change. Ruben Ramirez reports.

If you liked this article you might like

Pfizer's New Ideas, Ron Johnson's Disaster

Pfizer's Blah Quarter Points to Wyeth Deal

Pfizer's Blah Quarter Points to Wyeth Deal

Who Can You Antitrust?

Who Can You Antitrust?